1. INTRODUCTION

During the last few decades, zebrafish (Danio rerio) has grown as an important model organism for studying hematopoiesis and hematological diseases. Zebrafish and human share high similarity in genome and as high as 82% conservation in disease-associated genes. In addition, zebrafish have specific features, including high fecundity, external fertilization, and transparency at the early stages of development. With these unique features, zebrafish embryos are extremely suitable for imaging and high-throughput genetic or drug screenings. Particularly, the zebrafish blood system is highly conserved with mammals, with comparable hematopoietic cell contents, similar developmental process, regulatory mechanisms, and pathogenesis. Thus, zebrafish is an optimized organism for studying blood system development and for modeling human blood disorders.

The platelet is an essential component of blood cells and is mainly responsible for preventing bleeding by clotting. In mammals, platelets are anucleated cytoplasmic fragments of megakaryocytes (MKs), which differentiated from hematopoietic stem cells (HSCs). HSCs give rise to common lymphoid progenitors and common myeloid progenitors, which can differentiate into granulocyte/macrophage progenitors and MKs-erythrocyte progenitors (MEPs), respectively. MEPs are bipotent precursors that can produce both megakaryocytic cells and erythroid cells. The hematopoiesis process is highly conserved between zebrafish and mammals. Zebrafish HSCs originated in the ventral wall of the aorta, the mammalian aorta gonad mesonephros equivalents, and eventually seed the pronephros/kidney that is analogous to the bone marrow in mammals. In zebrafish, thrombocytes are the mammalian platelet equivalents. They appear in circulation at around 36 hpf, and also are derived from the thrombocyte and erythroid progenitors, the mammalian MEP equivalents, indicating the thrombocyte origin and lineage conservation between zebrafish and mammals.

In mammals, the developmental process for generating MKs is tightly controlled by several transcription factors. For example, GATA1 and FLI1 can bind the enhancers of multiple MK-specific genes and promote MEPs to differentiate into MKs. Besides transcription factors, cytokines are also critical for thrombopoiesis. Thrombopoietin (TPO) is a critical hematopoietic cytokine that can regulate the MK progenitor expansion and differentiation. The proliferation and maturation of MK progenitor cells depend on the circulating TPO by binding to the MPL receptor. Once TPO binds to MPL on the surface of the target cell, MPL dimerization occurs and the downstream tyrosine phosphorylation pathway is activated. The Janus kinase (JAK)/signal transducer and activation of transcription (STAT) pathway is one of the most important pathways for
thrombocytic cell expansion and differentiation, as STATs are finally activated by JAK2 kinase (JAK2) phosphorylation. In zebrafish thrombopoiesis, intrinsic pathways mediated by transcription factors and the extrinsic pathway induced by TPO are also conserved with mammals.

The well-known feature of platelets is the contribution to hemostasis and thrombosis. In mammalian, following the endothelial injury, the platelets are recruited to the site of injury and captured by platelet adhesive receptors such as glycoprotein (GP) Ib/IX interacted with collagen and von Willebrand factor (vWF). Platelet activation can also be induced by the coagulants such as thrombin, ADP, and thrombin A2 (TXA2) by binding with the protease-activated receptor/ADP receptors, respectively. Subsequently, the activation stimulates the platelet release reaction, such as the secretion of platelet α-granules and dense granule contents. Finally, the initial platelet plug is formed to seal the injured vessel. Once “platelet plug” is formed, coagulation factors induce a burst of thrombin production, and soluble fibrinogen converts to an insoluble fibrin clot that can constrict the fibrin mesh and strengthens the thrombus. Like mammals, zebrafish have a similar coagulation cascade, as their thrombocytes express the fibrinogen receptor GPIb (the vWF receptor) and can aggregate after stimulation with collagen, ADP, and vWF. Moreover, the thrombin receptors, protease-activated receptor, and the ADP receptors present on the zebrafish thrombocytes membrane. Thus, zebrafish have conserved hemostatic pathways in platelet function and coagulation.

The similarities between zebrafish and mammals in thrombocyte developmental and physiological processes indicate that the research progresses on zebrafish will shed light on the understanding of human platelet-related biology and diseases. The unique features of zebrafish, including the transparent embryos, coupled with fluorescent protein labeling methods permit it easy to visualize the interactions of thrombocyte cells and other components in vivo. The high fecundity and external fertilization make the zebrafish become a suitable model vertebrate in high-throughput studies on thrombopoiesis, hemostasis, thrombosis, and modeling human platelet-related diseases. Taking advantage of the zebrafish thrombocyte-specific transgenic lines such as Tg(cd41:EGFP) and Tg(iml:EGFP), combined with laser-induced injury technology and thrombocyte function evaluation approaches, more thrombocyte-related genes can be identified through functional screens, which will provide new insights for human platelet-related disorders. Here, we summarize recently developed methods for studying thrombocytes in zebrafish and review currently available zebrafish mutants for thrombocytic deficiencies and models for thrombocyte-associated disorders in detail (Table 1).

### 2. METHODS IN ZEBRAFISH FOR HEMOSTASIS AND COAGULATION RESEARCH

#### 2.1. Thrombocyte labeling

Selective labeling of zebrafish thrombocytes is important for tracing and isolating thrombocytic cells. In this case, the developmental, physiological, and pathogenetic changes of thrombocytes could be observed in vivo.

DiI-C18, a lipophilic fluorescent dye, has been shown to label thrombocytes in live zebrafish. Through injecting DiI-C18 into zebrafish, young thrombocytes with active function and high adhesion ability were marked with DiI-C18.

For stably labeling thrombocytes in zebrafish, one approach is to generate transgenic lines expressing fluorescent genes driven by a lineage-specific-promoter. CD41 is clearly expressed on the surface of platelets, MK/platelet progenitors, and early hematopoietic progenitors. Tg(cd41:EGFP) transgenic fish line is widely used for labeling HSPCs (GFPlow) and thrombocytes (GFPhigh) from embryonic stages to adulthood. The transcription factor GATA1 is a master regulator for erythropoiesis and thrombocytopoiesis. The zebrafish G1-GM2 line expresses GFP driven by GATA1 promoter, so erythrocytes and thrombocytes both are labeled in this transgenic line. The ETS family transcription factor FLI1 begins its expression in endothelial cells and interacts with GATA1 for both erythroid and megakaryocytic differentiation. Tg(fl1:eGFP) y1 lines could label endothelial cells as expected, and it also marks thrombocytes selectively.

Zebrafish mlp, the Tpo receptor, has been shown to be conserved with mammals and its expression is restricted in thrombocyte lineage. The Tg(iml:EGFP) line predominantly (~90%) marks thrombocytes and thrombocyte precursors in embryonic and larval stages. Zebrafish mylfp, a homolog for human myosin light chain 2 (MLC2) gene, MLC2 protein is essential for mammalian platelet function, and the MLC kinase and its phosphorylation in thrombocytes are conserved in zebrafish. Recently, Glo fish Tg(mylz2:RFP), a transgenic line with mylz2 promoter-driven RFP gene, has been generated and reported to label Dil-C18 young thrombocytes in zebrafish. They also generated GloFlI (Glo fish crossed with Tg(fl1:eGFP)) in which Dil-C18 and Dil-C18 thrombocytes are labeled with RFP and GFP, respectively.

These findings are definitely helpful in the identification of developing and functional thrombocytes and provide useful tools for the study of thrombopoiesis in zebrafish. Although achievements of thrombocyte labeling have been made in zebrafish, it is important to distinguish more diverse thrombocytes, such as apoptotic-related thrombocytes, immune response-related thrombocytes, and thrombocytes in specific developmental stages.

---

### Table 1

Summary of zebrafish models for thrombopoiesis and thrombosis disorders.

| Disorders | Related gene | Method | Phenotype |
|----------|--------------|--------|-----------|
| Congenital amegakaryocytic thrombocytopenia (CMT) | mpt | Mutation | Severe thrombocytopenia, bleeding tendency |
| Inherited thrombocytopenia (IT) | ptpyrg | Mutation | Small platelets, migration defects |
| Essential thrombocythemia (ET) | ntl2 | Mutation | Thrombocytes severe reduced, function decreased |
| Blood coagulation disorders | calr | Human mRNA overexpression | Thrombocytosis, HSC increased |
| Gray platelet syndrome (GPS) | jak2α-c [25] | mRNA overexpression | Thrombocytosis, erythrocytosis |
| Thrombocyte function-related genes | gray | Morpholino knockdown | Mild to moderate bleeding tendency |
| | gpr34l | Mutation | Thrombocyte aggregation defect |

---

www.blood-science.org
2.2. Thrombocyte quantification in zebrafish

The platelet count is an intuitonistic parameter to reflect the abundance of platelets in an organism. To quantify thrombocytes in zebrafish, several approaches can be applied in different developmental stages of animals. Whole-mount in situ hybridization (WISH) experiments can be performed to determine gene expression patterns with thrombocytopoietic lineage-specific probes at embryonic and larval stages.\(^\text{3}^9\) Lineage-specific transgenic reporter lines facilitate the quantification of thrombocytes, with fluorescent cell counts by antibody staining against fluorescent proteins or by flow cytometry analysis.\(^\text{27}^2\)

2.3. Thrombocyte functional assay in zebrafish

The predominant function of thrombocytes is aggregation when stimuli or injuries occur in the blood vessels. In order to visualize thrombocytes aggregation and adhesion in vivo, several approaches are reported to introduce the injuries into the blood system:

1. **By punching:** Embryos can be injured by puncturing the blood vessel in the tail region with a glass needle, and the bleeding status can be observed under the microscope.\(^\text{40}^\)

2. **By chemical induction:** Vascular occlusion can be induced by specific chemicals. FeCl\(_3\) is reported to cause endothelial injury by free radical production,\(^\text{41}^\) and it can induce zebrafish vascular occlusion in the caudal artery.\(^\text{31,42}\) Besides FeCl\(_3\), phenylalanine can also lead to arterial thrombus formation of zebrafish larvae.\(^\text{42}\)

3. **By laser injury:** Pulsed nitrogen laser light has previously been used to cause a vessel lesion that can cause the formation of the vascular occlusion.\(^\text{43}\) It is very easy to use myotomes as reliable markers for repeatedly selecting the exact location of the vessel for injury in zebrafish, while it is difficult to consistently target the same vessel locations in mammalian models.\(^\text{28}\)

To evaluate the thrombocyte activation and adhesion abilities, several parameters can be utilized in zebrafish similar to mammals. Due to the transparency of fish embryos and larvae, the thrombus formation, growth, and dissolution can be visualized in live animals under the microscope. It is accessible to detect the time to attachment, the time when the first cell adheres to the injury site. Time to attachment represents the thrombus initiation ability, including thrombocyte activation, and thrombocyte–subendothelium interactions.\(^\text{44}\) It is also easy to calculate the time to occlusion of the vessel corresponding to the thrombus growth ability, including thrombocyte activation and aggregation.\(^\text{45}\) In addition, the thrombus surface area can also be utilized in zebrafish for a better understanding of thrombus growth ability.\(^\text{46}\) To monitor the thrombus stability and retraction, the time to dissolution could be recorded in zebrafish.\(^\text{43}\) In adult zebrafish, a direct way to analyze the function of thrombocytes is to cut the caudal region and calculate the bleeding time. The aggregation of thrombocytes can also be monitored by a tilt plate assay in vitro. By observing a certain volume of blood in PBS (containing coagulants) in a tilt plate, aggregation and adhesion can be evaluated by the firm button formation and the migration speed.\(^\text{46}\)

These approaches are undoubtedly useful for the evaluation of thrombocyte-related functions in zebrafish. Along with our developing learning on new functions of thrombocytes, new evaluation methods or parameters should be developed on time for the extensive application of zebrafish model.

3. UNDERSTANDING THROMBOCYTE-RELATED DISORDERS USING ZEBRAFISH

3.1. Thrombocytopenia

Thrombocytopenia is a kind of disorder mainly manifested as a low platelet count, characterized by easy bruising and increased bleeding risk, and the severe bleeding can become life-threatening. Thrombocytopenia caused by gene mutations can be precisely resembled in animal models. Several kinds of gene-related thrombocytopenia have been studied in zebrafish, including the following.

3.1.1. Congenital amegakaryocytic thrombocytopenia (CAMT) and the related gene MPL

CAMT is a rare bone marrow failure syndrome characterized by severe thrombocytopenia.\(^\text{47}\) CAMT patient is characterized by reduced MKs, increased bleeding tendency, and predisposed to aplastic anemia.\(^\text{47–49}\) Mutations in MPL has been demonstrated as the cause of CAMT.\(^\text{50}\) MPL gene encodes for myeloproliferative leukemia protein, the receptor for TPO. TPO–MPL is the most important pathway regulating platelet in both mammals and vertebrates.\(^\text{51}\) The transgenic c-MPL-deficient mice show significant thrombocytopenia and defective megakaryocytopoiesis\(^\text{51}\) and a reduction in hematopoietic progenitor cells.\(^\text{52}\) In zebrafish, knockdown of the *mpl* gene by morpholino effectively eliminated the numbers of circulating thrombocytes \((cd41;GFP^+\text{ cells})\).\(^\text{27}\) Lin et al generated an inheritable zebrafish *mpl* mutant and showed that disruption of *mpl* led to a severe reduction of thrombocytes from embryonic stage to adulthood by proliferation defection of the thrombocyte precursors, as well as deficiencies in adult HSPCs.\(^\text{17}\) Similar to CAMT patients, *mpl* mutation zebrafish display deficient hemostasis and increased bleeding tendency. Moreover, due to the restricted expression of *mpl* in thrombocytopoietic lineage, the transgenic reporter line Tg(*mpl:eGFP*) labels thrombocytes selectively. Together with Tg(*mpl:eGFP*) transgenic line, the CAMT model can serve as a precise model for anti-CAMT drug evaluation and screening, as well as for understanding TPO/MPL-dependent or TPO/MPL-independent thrombocytopoiesis.

3.1.2. Inherited thrombocytopenia (ITs) and zebrafish-related mutants

ITs are a group of heterogeneous disorders, with genetic mutations in genes associated with MK differentiation and/or platelet formation, characterized by a reduced platelet count and impaired hemostasis.\(^\text{53}\) Due to extensive application of high-throughput sequencing, increasing numbers of causative genes have been revealed to result in different forms of IT.\(^\text{53}\) Taking advantages of zebrafish gene manipulation approaches and its drug development potential, several IT-associated genes have been targeted in zebrafish for generating IT-like zebrafish models.

3.1.3. IT and PTPRJ (CD148)

**PTPRJ** (CD148) is a receptor-like protein tyrosine phosphatase that is expressed highly in MKs and platelets in human. PTPRJ plays a pivotal role in mediating platelet aggregation in hemostasis and thrombosis formation by inactivating the Src family kinases.\(^\text{54,55}\) Recently, it is reported that human patients with PTPRJ mutations presented as nonsyndromic thrombocytopenia with the following characteristics: spontaneous bleeding, an increased proportion of small platelets, MK maturation deficiency, and impaired platelet responses to the GPVI agonists collagen and convulxin.\(^\text{56}\) To confirm that the PTPRJ gene is the IT causative gene, the authors generated a *ptpra* zebrafish mutant by CRISPR/Cas9 and found...
that the mutant fish showed decreased cd41+ thrombocytes, which recapitulates the PTPRJ-deficient patient IT syndromes. Consistently, the Ptpn' mutant mice showed bleeding tendency and were unable to form arterial thrombosis, suggesting that PTPRJ is a positive regulator of platelet activation and thrombosis. These findings advance our understanding on the PTPRJ roles in platelet development and functions as well as in pathogenesis.

3.1.4. Nuclear factor erythroid 2 (NFE2) causes IT in animal models. NFE2 is a member of the basic zipper (bZIP) and CAPn'Collar (CNC) superfamily that regulates gene transcription. NFE2 has been found to be associated with myeloproliferative disorders, polycythemia vera, and myelofibrosis. NFE2 gene is expressed in hematopoietic progenitor cells, myeloid, erythroid, and MK lineages and regulates proplatelet formation by promoting the MK maturation in mice. The Nfe2 mutant mice showed an absence of circulating platelets, which led to the death of the mice due to extensive hemorrhage. In zebras, nfe2 mutants showed bleeding tendency because of the expression of adams13. Moreover, when induced by histone, shadams13 increased the cd41+GFP+ thrombocytes and the expression of thrombocyte markers, resembling the ET phenotype. zebra mutant mice showed an early thrombocytosis because of the expression of jak2v617f in the MKs. Yet, inheritable jak2v617f zebras are still needed for stably modeling human ET pathogenesis and for drug development.

3.2. Essential thrombocytopenia (ET)

ET is a kind of Philadelphia chromosome-negative chronic myeloproliferative disorder, with high incidence of thrombosis and hemorrhage. Generally, thrombocytosis and platelet dysfunction are responsible for the thrombo-hemorrhagic phenomena in ET. It has been reported that several genes are associated with ET, such as JAK2, CALR, and MPL.

3.2.1. ET and JAK2. JAK/STAT pathways are important for mediating the cytokine receptor function. JAK2 that belongs to the JAK family plays an important role in hematopoiesis regulation. A gain-of-function V617F mutation in the JH2 domain of JAK2 (Jak2v617f) was identified in myeloproliferative disease (MPD) and ET patients. In zebras, overexpressing jak2v617f (an ortholog of human Jak2v617f) mutation could significantly increase Stat5 phosphorylation and induce a significant increase in erythropoiesis. Overexpressing jak2v617f increased the cd41+GFP+ thrombocytes and the expression of thrombocyte markers, resembling the ET phenotype. zebra mutant mice showed an early thrombocytosis because of the expression of jak2v617f in the MKs. Yet, inheritable jak2v617f zebras are still needed for stably modeling human ET pathogenesis and for drug development.

3.3. Platelet function-related disorders

3.3.1. Gray platelet syndrome (GPS) and NBEAL2. GPS is a predominantly recessive platelet disorder characterized by mild thrombocytopenia with large platelets, a-granule deficiency, and hemorrhages. NBEAL2 (neurobeachin-like 2), which is highly expressed in MKs and granulocytes and is upregulated during the generation of MKs, plays an important role in MK a-granule development. Researchers have utilized genomic DNA sequencing to identify the NBEAL2 as the causative gene for GPS. Albers et al. confirmed that knockdown of nbeal2 in zebras led to a complete thrombocyte abrogation and spontaneous bleeding resembling mammalian GPS symptoms.

3.4. Understanding thrombocyte regulation in zebras

3.4.1. GPR34. GPR34 is an orphan G protein-coupled receptor, and it belongs to the P2Y12-like receptor group within the family of rhodopsin-like receptors. The P2Y12-like receptor group comprises the ADP receptors (P2Y12, P2Y13) and the orphan receptors (GPR34, GPR87, GPR82). The cAMP is a crucial physiological function of zebras, which is highly expressed in MKs and granulocytes and is upregulated during the generation of MKs, plays an important role in MK a-granule development. Researchers have utilized genomic DNA sequencing to identify the NBEAL2 as the causative gene for GPS. Albers et al. confirmed that knockdown of nbeal2 in zebras led to a complete thrombocyte abrogation and spontaneous bleeding resembling mammalian GPS symptoms.

4. CONCLUSION AND SPECULATION

The zebras have become a model system with a number of unique features that make it a powerful tool for studying
thrombocyte development and disorders during the past decades. Taking advantage of zebrafish thrombocyte-specific markers and lines, the zebrafish is compatible with both traditional and advanced molecular, cellular, and genetic approaches to study thrombocyte biology and pathology in an intact organism. More and more thrombocyte disorders, including CAMT, IT, and ET, and several platelet functional disorders have been resembled successfully in zebrafish, and these zebrafish lines serve as valuable tools for verification of human ortholog gene functions in hematopoiesis and pathogenesis, evaluation of drug responses and risks, and screening of novel genetic and chemical modifiers in thrombocytopenia. Despite these progresses, still many clinically common diseases, such as immune thrombocytopenia, need to be modeled in zebrafish for drug discovery. In summary, the zebrafish provides a powerful model system to study hematopoietic and hemostatic disorders, and these zebrafish models will greatly facilitate the discovery of new molecular processes and novel chemical compounds for thrombopoiesis and thrombocyte-related disorders in the future.

REFERENCES

[1] Howe K, Clark MD, Torroja CF, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature 2013;496(7446):498–503.
[2] Davidson AJ, Zon LI. The ‘definitive’ (and ‘primitive’) guide to zebrafish hematopoiesis. Oncogene 2004;23(43):7233–7246.
[3] Geddiss AE. Megakaryopoiesis. Semin Hematol 2010;47(3):212–219.
[4] Orkin SH, Zon LI. Hematopoietic: an evolving paradigm for stem cell biology. Cell 2008;132(4):631–644.
[5] Paik Ej, Zon LI. Hematopoietic development in the zebrafish Int J Dev Biol 2010;54(6–7):1127–1137.
[6] Jagadeeswaran P, Sheehan JP, Craig FE, Troyer D. Identification and characterization of zebrafish thrombocytes. Br J Haematol 1999;107(4):731–738.
[7] Gregory M, Jagadeeswaran P. Selective labeling of zebrafish thrombocytes: quantitation of thrombocyte function and detection during development. Blood Cells Mol Dis 2002;28(3):418–427.
[8] Svoboda O, Stachura DL, Machonova O, et al. Dissection of vertebrate hematopoiesis using zebrafish thrombopoietin. Blood 2014;124(2):220–228.
[9] Eibach M, Holmes ML, Newton A, et al. Expression pattern can be recapitulated in living transgenic zebrafish using GFP reporter gene. Development 1997;124(20):4105–4111.
[10] Nachmiyas VT, Yoshida K, Glenon MC. Lowering pH in blood platelets dissociates myosin phosphorylation from shape change and myosin association with the cytoskeleton. J Cell Biol 1987;103(4):1761–1769.
[11] Hitchcock IS, Kaushansky K. Thrombopoietin from beginning to end. Blood 2004;103(10):3427–3429.
[12] Starck J, Cohen N, Gonen C, et al. Functional cross-antagonism between transcription factors FLI-1 and EKLF. Mol Cell Biol 2014;34(1):1390–1402.
[13] Kaushansky K, Broady VC, Lin N, et al. Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A 1995;92(8):3234–3238.
[14] Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005;115(12):1333–1347.
[15] Drachman JG, Millet KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem 1999;274(19):13480–13484.
[16] Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F, Rahim F. Molecular basis for ADP-induced platelet activation. J Thromb Haemost 2010;8(11):2866–2872.
[17] Gellert M, Goldwasser P, Barondess J, et al. Establishment of a congenital megakaryocytic thrombocytopenia model and a thrombocyte-specific reporter line in zebrafish. Leukemia 2016;31(5):1206–1216.
[18] Collor B. Historical perspective and future directions in platelet research. J Thromb Haemost Suppl 1:374–395.
[19] Farndale RW, Sinna JJ, Barnes MJ, de Groot PG. The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2004;2(4):561–573.
[20] Andrews RK, Gardiner EE, Shen Y, Whistock JC, Berndt MC. Glycoprotein Ib-IX-V. Int J Biochem Cell Biol 2003;35(8):1170–1174.

www.blood-science.org
King S, Germeshausen M, Strauss G, Welte K, Ballmaier M. Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. Br J Haematol 2005;131(5):636–644.

Ballmaier M, Germeshausen M. Advances in the understanding of congenital amegakaryocytic thrombocytopenia. Br J Haematol 2009;146(1):3–16.

Ibarra K, Iishi E, Eguchi M, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A 1999;96(16):3132–3136.

Murone M, Carpenter DA, de Sauvage FJ. Hematopoietic deficiency in c-mpl and TPO knockout mice. Stem Cells 1998;16(1):1–6.

Kirimura S, Roberts AW, Metcalf D, Alexander WS. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thromboxane. Proc Natl Acad Sci U S A 1998;95(3):1195–1200.

Almazni I, Stapley R, Morgan NV. Inherited thrombocytopenia: update on genes and genetic variants which may be associated with bleeding. Front Cardiovasc Med 2019;6:80.

Mori J, Nagy Z, Di Nunzio G, et al. Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148. Blood 2018;131(10):1224–1144.

Senis YA, Tomlinson MG, Ellison S, et al. The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis. Blood 2009;113(20):4942–4954.

Marconi C, Di Buduo CA, LeVine K, et al. Loss-of-function mutations in PTPRJ cause a new form of inherited thrombocytopenia. Blood 2019;133(12):1346–1357.

Tsibou N, Utsunomiya T, Roberts RL, et al. The tyrosine phosphatase CD148 interacts with the 85 regulatory subunit of phosphoinoside 3-kinase. Biochim J 2008;413(1):193–200.

Andrews NC. The NF-E2 transcription factor. Int J Biochem Cell Biol 1998;30(4):429–432.

Jutzi JS, Bogeska R, Nikoloski G, et al. MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. J Exp Med 2015;210(5):1003–1019.

Tijssen MR, Ghevaert C. Transcription factors in late megakaryopoiesis. Int J Biochem Cell Biol 2011;43(8):735–748.

Shvidasani RA, Orkin SH. Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2. Proc Natl Acad Sci U S A 1999;92(19):8690–8694.

Rost MS, Shettopolov I, Liu Y, et al. Nfe2 is dispensable for early but required for adult thrombocyte formation and function in zebrafish. Blood Adv 2018;2(23):3418–3427.

Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood 2017;130(10):1181–1188.

Kramer HJ, George JN. Hereditary thrombotic thrombocytopenic purpura. N Engl J Med 2019;381(17):1655–1662.

Schizas A, Worretz K, Piskunek C, et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood 2012;119(25):6228–6235.

Jin SY, Xiao J, Bao J, Zhou S, Wright JF, Zheng XL. AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura. Blood 2013;121(19):3825–3829. S1–3.

Zheng L, Abdelgawad MS, Zhang D, et al. Histone-induced thrombotic thrombocytopenic purpura in adams13−/− zebrafish depends on von Willebrand factor. Haematologica 2019.

Ashorobi D, Gohari P. Essential Thrombocytosis (Essential Thrombocythemia), E1. 2019.

Rane SG, Reddy EP. JAKs, STATs and Src kinases in hematopoiesis. Oncogene 2013;32:3334–3358.

Ugo V, James C, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Med Sci (Paris) 2005;21(6–7):669–670.

Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythaemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7(4):387–397.

Ma AC, Fan A, Ward AC, et al. A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythaemia vera. Exp Hematol 2009;37(12):1379–1386. e4.

Mansier O, Kilian B, Gurtav AT, et al. Description of a knock-in mouse model of JAK2(V617F) MPN emerging from a minority of mutated hematopoietic stem cells. Blood 2019;134(26):2383–2387.

Michalak M, Groenendyk J, Szabo E, Gold LÍ, Opas M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 2009;417(3):651–668.

Olbeid M, Testiere A, Ghirlandelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13(1):54–61.

Nanney LB, Woodrell CD, Greives MR, et al. Calreticulin enhances porcine wound repair by diverse biological effects. Am J Pathol 2008;173(3):610–630.

Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369(23):2391–2405.

Lim KH, Chang YC, Chang YH, et al. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish. Blood Cancer J 2016;6(10):e481.

Norden AT, Norden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev 2007;21(1):21–36.

Albers CA, Cvjec A, Favier R, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet 2011;43(8):735–737.

Kahr WH, Hindley J, Li L, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet 2011;43(8):738–740.

Plutero FG, Di Paola J, Carcao MD, Kahr W. NBEAL2 mutations and bleeding in patients with gray platelet syndrome. Platelets 2018;29(6):632–635.

Deppermann C, Cherpokova D, Norden P, et al. Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice. J Clin Invest 2013;123(1):692–701.

Schoenberg T, Hermendorf T, Engesmaier E, et al. Structural and functional evolution of the P2Y(12)-like receptor group. P fl Int J Biochem Cell Biol 2013;pii: 69210.

Marquis NR, Vigdahl RL, Tavormina PA. Platelet aggregation. I. Regulation by cyclic AMP and prostaglandin E1. J Exp Med 1969;128(3):963–972.

Foster CJ, Prosser DM, Agans JM, et al. Molecular identifi cation and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Exp Med 2001;194(12):1591–1598.

Kim S, Alrabahi A, Zafreen L, et al. G protein-coupled receptor gpr34l mutation affects thrombocyte function in zebrafish. Br J Haematol 2018;180(3):412–419.